Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company focused on advanced therapies for the sports medicine and severe burn care markets. Its news flow centers on financial performance, adoption of its cell therapy and biologic products, and progress in clinical and manufacturing initiatives.
Investors following VCEL news can expect regular quarterly earnings releases detailing total revenue, product-level revenue for MACI and Burn Care (Epicel and NexoBrid), gross margin, net income or loss, adjusted EBITDA and operating cash flow. Vericel frequently provides financial guidance ranges for full-year revenue, MACI growth, gross margin and adjusted EBITDA margin, and may update these expectations as the year progresses.
Company updates also highlight operational metrics such as record MACI revenue, numbers of MACI implants and biopsies, growth in trained MACI Arthro surgeons, Epicel and NexoBrid biopsy and hospital order trends, and expansion of the MACI sales force. These disclosures offer insight into market penetration and utilization of Vericel’s therapies in orthopedic and burn care settings.
Vericel news items often include information on clinical and regulatory milestones, such as FDA IND clearance for the Phase 3 MACI Ankle clinical study and the initiation of the MACI Ankle MASCOT clinical trial. The company also announces participation in major investor and healthcare conferences, including events hosted by J.P. Morgan, Stephens, Wells Fargo and Truist Securities, where management discusses business performance and strategy.
This VCEL news page aggregates these press releases and related announcements so readers can review historical and recent developments around Vericel’s financial results, product adoption, clinical programs and corporate presentations in one place.
Vericel (NASDAQ:VCEL) announced FDA approval to commercially manufacture MACI at its new Burlington, Massachusetts cell therapy facility. The approval permits commercial production to begin in Q2 2026, increases manufacturing capacity to support long-term growth, and enables potential MACI commercialization outside the U.S.
This milestone strengthens the company’s supply chain and positions Vericel to scale MACI production to meet rising demand for restorative cartilage repair therapies.
Vericel (NASDAQ:VCEL) will present at multiple investor conferences in March 2026. The company confirmed presentations at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, and the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026.
A webcast of the presentations will be available via the company's investor relations website.
Vericel (NASDAQ:VCEL) reported strong fourth-quarter and full-year 2025 results: total revenue $276.3M, MACI revenue $239.5M (+21% YoY), and record Q4 gross margin of 79%. Full-year adjusted EBITDA rose to $70.9M (26% margin) and the company holds approximately $200M cash with no debt. Management provided 2026 guidance: total revenue of $316–$326M, MACI revenue of $280–$286M, and ~75% gross margin.
Q4 highlights included record MACI implants and salesforce expansion; the company remains on track for commercial manufacturing and a UK MHRA submission in 2026.
Vericel (NASDAQ:VCEL) will report fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026.
Management will host a conference call and webcast at 8:30 a.m. ET. Presentation slides will be available on the Investor Relations website and a replay will be available through February 26, 2027. Telephone participants may dial 800-330-6730 or +1-312-471-1351 with passcode 227995.
Vericel (NASDAQ:VCEL) reported preliminary, unaudited 2025 results: total revenue ~$276 million comprising MACI revenue $239.5 million and Burn Care $36.5 million. Gross margin is expected at 74% and adjusted EBITDA margin at 26%. The company expects GAAP net income for the second consecutive year and ended the period with $200 million cash and investments and no debt. Q4 marks the highest quarterly counts since launch for MACI implants, implanting surgeons, surgeons taking biopsies, and MACI biopsies, with MACI revenue growth of 20%+ for a third straight year. Completed MACI sales force expansion, >900 MACI Arthro trained surgeons, initiated the MACI Ankle MASCOT study, and remain on track to begin commercial manufacturing at a new facility in 2026.
Vericel (NASDAQ:VCEL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on the company’s Investor Relations website at http://investors.vcel.com.
Vericel (NASDAQ:VCEL) will present a fireside chat at the Stephens Annual Investment Conference on Thursday, November 20, 2025 at 11:00 a.m. ET (10:00 a.m. CT).
A live webcast will be available via the company’s Investor Relations website at http://investors.vcel.com, allowing investors and analysts to view the presentation in real time.
Vericel (NASDAQ:VCEL) reported record third-quarter 2025 results with $67.5M total revenue and MACI revenue up 25% to $55.7M. Gross margin was 73.5%, net income was $5.1M (or $0.10 diluted EPS), and non-GAAP adjusted EBITDA rose 69% to $17.0M (25% of revenue). Operating cash flow was a record $22.1M. Burn care revenue totaled $11.8M (Epicel $10.4M; NexoBrid $1.5M) with NexoBrid quarterly revenue up 38% year-over-year. Cash and investments totaled $185M with no debt. The company reaffirmed 2025 guidance of $272–$276M total revenue and ~74% gross margin.
Vericel (NASDAQ:VCEL) will report its third-quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss financial results and business highlights.
Investors can access the live webcast and presentation slides at http://investors.vcel.com/events-presentations. A replay of the webcast will be available until November 6, 2026. Telephone participants may call 800-330-6730 (U.S.) or +1-312-471-1351 (international) and use passcode 476633.
Vericel Corporation (NASDAQ:VCEL), a specialist in advanced therapies for sports medicine and severe burn care, will participate in a fireside chat at the Wells Fargo Healthcare Conference. The presentation is scheduled for September 4, 2025, at 3:45 p.m. ET. Investors can access the webcast through Vericel's investor relations website at investors.vcel.com.